Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139682 | 1.00 | KDM4C (0.60) | KDM4CGRM2DHFRCHRNB2CHRNA4 | |
| SCHEMBL17609132 | 0.88 | KDM4C (0.58) | KDM4CGRM2DHFRIP6K1USP2 | |
| SCHEMBL17609100 | 0.85 | KDM4C (0.56) | KDM4CGRM2 | |
| SCHEMBL30139683 | 0.85 | KDM4C (0.56) | KDM4CGRM2 | |
| SCHEMBL17602152 | 0.82 | KDM4C (0.65) | KDM4CGRM2DHFRCETP | |
| SCHEMBL29542623 | 0.82 | KDM4C (0.65) | KDM4CGRM2DHFRCETP | |
| SCHEMBL17609163 | 0.77 | KDM4C (0.54) | KDM4C | |
| SCHEMBL30139680 | 0.77 | KDM4C (0.54) | KDM4C | |
| SCHEMBL17602155 | 0.73 | KDM4C (0.50) | KDM4CGRM2DHFRCHRNB2CHRNA4 | |
| SCHEMBL17602292 | 0.73 | KDM4C (0.58) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10611763-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3193601-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044429-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611763-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885GRM2 2310/4885DHFR 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.